Published in Gene Therapy Weekly, February 3rd, 1997
The overall five-year survival rate for ovarian cancer is a dismal 37 percent. Poor survival rates are related directly to the late stage of detection of this disease. There are no reliable early diagnostic procedures, so the burden of improving survival rates currently falls on therapeutic procedures.
Kian Behbakht and colleagues from the University of Pennsylvania tested the feasibility of adenovirus-mediated...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.